N-[3-(N'-Hydroxycarbamimidoyl)phenyl]-2-(morpholin-4-yl)acetamide

Catalog No. :
ACLQGC345
CAS No. :
863669-04-9
Molecular Formula :
C13H18N4O3
Molecular Weight :
278.31

IUPAC Name:(Z)-N-(3-(N'-hydroxycarbamimidoyl)phenyl)-2-morpholinoacetamide

N-[3-(N'-Hydroxycarbamimidoyl)phenyl]-2-(morpholin-4-yl)acetamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$186.00Login to see priceInquiryInquiry
100mg95%$269.00Login to see priceInquiryInquiry
250mg95%$378.00Login to see priceInquiryInquiry
1g95%$782.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameN-[3-(N'-Hydroxycarbamimidoyl)phenyl]-2-(morpholin-4-yl)acetamide
IUPAC Name(Z)-N-(3-(N'-hydroxycarbamimidoyl)phenyl)-2-morpholinoacetamide
MDL No.MFCD07339125
Molecular FormulaC13H18N4O3
Molecular Weight278.31
SMILESO=C(NC1=CC=CC(/C(N)=N/O)=C1)CN2CCOCC2
InChI KeyIAAQXEXNTWTPMT-UHFFFAOYSA-N
Synonym4-Morpholineacetamide, N-[3-[(hydroxyamino)iminomethyl]phenyl]-;N-[3-(N'-Hydroxycarbamimidoyl)phenyl]-2-(morpholin-4-yl)acetamide
CAS No.863669-04-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACLQGC345 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLQGC345 route product structure diagram
    ACLQGC345863669-04-9
Inquiry

2. ACLQGC345 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACMWYH185 route compound structure diagram
    ACMWYH1853235-69-6 In Stock
  4. Then
  5. ACLQGC345 route product structure diagram
    ACLQGC345863669-04-9
Inquiry

Comments (0)